<DOC>
	<DOCNO>NCT00421928</DOCNO>
	<brief_summary>The purpose trial evaluate effectiveness ( level pain control ) safety orally administer tapentadol ( CG5503 ) Extended Release ( ER ) ( base ) dose 100-250 mg twice daily patient moderate severe chronic pain due osteoarthritis knee , comparison placebo Oxycodone Controlled Release ( CR ) .</brief_summary>
	<brief_title>Tapentadol ( CG5503 )</brief_title>
	<detailed_description>The primary objective randomize ( study medication assign patient chance ) , double-blind ( neither patient investigator know study medication ) , phase III , placebo active control trial evaluate efficacy safety orally administer tapentadol ( CG5503 ) Extended Release ( ER ) ( base ) dose 100-250 mg twice daily patient moderate severe chronic pain osteoarthritis ( OA ) knee . The study conduct registration approval tapentadol ( CG5503 ) US outside US . The trial consist five period : screening ( assess eligibility ) , washout ( 3-7 day determination baseline pain intensity ) , titration ( dose 3 week optimal individual level ) , maintenance ( investigational drug intake 12 week adjustment allow ) , follow-up ( 2 week post treatment discontinuation ) . The study hypothesis study drug effective placebo reduce patient pain intensity . The Secondary objective include collection pharmacokinetic ( related body use drug ) information dose verification . The trial objective assess compare baseline pain level level week 12 maintenance phase . This do look patient 's pain diary information . Titrate tapentadol ( CG5503 ) ER ( extended release ) 50mg patient 's optimal dose range 100mg 250mg twice day ; Oxycodone CR ( control release ) 10mg 50mg twice day ; Placebo ( active ingredient ) . All dose trial treatment take orally approximately 120 mL water without food maximum timeframe 15 week .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>Patients diagnose osteoarthritis knee base American College Rheumatology ( ACR ) criteria functional capacity class IIII patient take analgesic medication least 3 month prior screen and/or dissatisfy current therapy Patients require opioid treatment must take daily dos opioidbased analgesic , equivalent &lt; 160 mg oral morphine baseline score great equal 5 11point numerical rating scale , calculated average pain intensity last 3 day prior randomization . History alcohol and/or drug abuse Investigator 's judgement history significant liver insufficiency chronic hepatitis B C , HIV , presence active hepatitis B C within past 3 month lifelong history seizure disorder epilepsy history malignancy within past 2 year , exception basal cell carcinoma successfully treat uncontrolled hypertension patient severely impaired renal function patient moderate severly impair hepatic function laboratory value reflect inadequate hepatic function</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Chronic Pain</keyword>
	<keyword>Osteoarthritis , Knee</keyword>
	<keyword>tapentadol</keyword>
	<keyword>Pain Assessment</keyword>
</DOC>